| Literature DB >> 32461687 |
Muhammad Imran Omar1, Monique J Roobol2, Maria J Ribal3, Thomas Abbott4, Paul-Michael Agapow5, Sonia Araujo6, Alex Asiimwe7, Charles Auffray8, Irina Balaur8, Katharina Beyer9, Chiara Bernini10, Anders Bjartell11, Alberto Briganti12, John-Edward Butler-Ransohoff7, Riccardo Campi3, Marinel Cavelaars13, Bertrand De Meulder8, Zsuzsanna Devecseri14, Marc Dietrich Voss14, Konstantinos Dimitropoulos3, Susan Evans-Axelsson11, Billy Franks4, Louise Fullwood15, Denis Horgan10, Emma Jane Smith3, Amit Kiran4, Kati Kivinummi16, Mark Lambrecht17, Doron Lancet18, Peter Lindgren19, Sara MacLennan20, Steven MacLennan20, Maria Manuela Nogueira8, Fredrik Moen19, Maxim Moinat13, Kishore Papineni4, Christian Reich6, Kristin Reiche21, Stijn Rogiers17, Claudio Sartini7, Kees van Bochove13, Femke van Diggelen22, Mieke Van Hemelrijck9, Hein Van Poppel3, Jihong Zong7, James N'Dow3.
Abstract
Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.Entities:
Mesh:
Year: 2020 PMID: 32461687 DOI: 10.1038/s41585-020-0324-x
Source DB: PubMed Journal: Nat Rev Urol ISSN: 1759-4812 Impact factor: 14.432